Newest Issue is Out. Get your exclusive copy today.
A winning strategy is essential to reach or accomplish goals in pharmaceutical industry. However, maintaining the excellence of Strategic Drug Development Services is a necessary stipulation for the Strategic evolution for Pharma companies. The technologies leading to Pharmaceutical regulatory strategy and Pharmaceutical strategic developments are at the limits of human knowledge. The huge size of the companies, organizations and the complexities of their technologies and processes present many challenges. On the other hand, strategy development and distribution system is highly costly to implement. The effective Pharma strategies can help to generate business exposure, relationship building, and market research. Thus, they are important initiatives to boom overall business in the long term.
Right now all over the world crossfunctional teams in pharma biotech medtech and other life science companies are working on their strategic plans Large or small companies usually follow this annual ritual
The AsiaPacific APAC region is no stranger to confronting and defeating disease outbreaks From SARS and Avian influenza to MERS and HN the regions economies have demonstrated remarkable resilience and with each new occurrence found themselves better prepared to confront the challenge
Modelling and simulation has been growing rapidly in impact and is now actively used by biopharmaceutical companies worldwide for drug development and regulatory agencies for review and approval
There is a widespread panic around the world about COVID caused by the novel Coronavirus In late December China health Officials reported an outbreak of pneumonia of unknown origin in Wuhan Hubei province The World Health Organisation WHO originally called this disease Novel Coronavirusinfected Pneumonia NCIP and this novel coronavirus was provisi...
China and India are the leading players in bulk drugs and manufacture more than per cent of global bulk drug China is the largest bulk drug supplier in world and India is second As reported by ministry of commerce India exported drugs formulation and biologicals of billion USD in which increased to billion USD in increase
Viral outbreaks are not new to the world Before COVID we had other outbreaks such as Ebola in Swine Flu HN in and Severe Acute Respiratory Syndrome SARS outbreak in But the COVID outbreak became a pandemic and broke the record of all viral outbreak in past years forcing the World Health Organization WHO to declare health emergency globally
Despite the hype the routine use of AI in marketing in the life sciences is a long way away
Leading in todays culturally diverse workplaces with multidimensional processes and stakeholders requires individuals to adapt to new environments learn new skills and manage a range of stresses and strains between the interface of professional and personal life
The Pharmaceutical industry has been growing in parallel to human evolution
In the WHO published an article in its Drug Information Bulletin titled Collaboration not competition developing new reliance models The articles authors argued that modern medicines manufacture and distribution were becoming more and more globalized and that as a consequence the manufacturing processes and supply chains of pharmaceutical products...
When researching my latest book life sciences CEOs told me that the most important and fulfilling part of their job was developing the people who worked for them
Let me put up the disclaimers up front I have been an employee in the Indian pharma industry and currently run a consultancy business where several leading pharma companies are our clients
Pharmacovigilance has undergone tremendous changes since the Vioxx story in which triggered the risk management approach worldwide
Personalised medicine is going to change the shape of the pharmaceutical market in the years to come
As per ICH QA guidelines impurity in a drug substance is any component of the drug substance that is not the chemical entity defined as the drug substance and as per ICH QB guidelines impurity in any component of the drug product that is not the chemical entity defined as the drug substance or an excipient in the drug product
A marriage between blockchain and the pharma supply chain is not preordained
In todays fast paced world of biopharmaceutical innovation no one individual or single organisation can really work alone
Gone are the days when line managers used to visit once in a while for joint working with their team members for a few days meet some important doctors and before leaving issue stern instructions to the team members that they should meet their targets without fail failing which they may not be in the team for long
Since autumn the first package of costcutting measures in Switzerlands healthcare system is being reviewed One of the measures is the socalled reference price system for pharmaceutical whose patents have expired The Government Health Department has given two models to the consultation
Allow yourself a moment to dream Imagine that you could give your medical marketing team superpowers What would they be Being invisible would allow your marketers to watch competitors as they work Being able to read the minds of key opinion leaders would make your medical affairs team incredibly insightful Time travelling market access teams could...
What is Blockchain A Blockchain is a global distributed ledger or database running on millions of devices and open to anyone where information and particularly anything of value can be moved and stored securely and privately Tapscott et al On the Blockchain trust and integrity amongst strangers is established not by intermediaries but through mass...
Seventy years ago average life expectancy globally was today it is Seventy years ago million people worldwide were infected with smallpox today none The disease is eradicated Thanks to initiatives such as Gavi the Vaccine Alliance more than per cent of children now get early immunisation
In ethically promoting Pharma business field force are the resources who generate prescriptions for the products being promoted thus bring in revenue therefore the figures at the top of the line always depend upon their contribution However not all members of the field force are consistently hitting the numbers If we enable most of the field force...
The increasing cost of research in the west the ongoing tightening of regulations and pricing policies and major funding cuts for biomedical research have led to an increased interest in the outsourcing of clinical trials Not only is the APAC pharma market growing faster than the rest of the world it has a large treatment nave population and has sh...
Perhaps not as rampantly in the developed countries but definitely in the developing countries and especially in India access to medicines comes first even earlier than the access to healthcare facilities or doctors This essentially means that come illness most likely one would swallow a pill first and then visit a doctor if at all deemed neces...
Recent legislation has forced the Chinese regulatory environment to evolve establishing a friendlier environment for pharmaceutical development These changes may opendoors for pharmaceutical companies but they also create the need to adapt to the fastchanging regulatory requirements and the uncertainty that comes with legislative change The...
China is the second largest pharmaceutical market in the world according to a Top Markets Report on the countrys pharmaceutical industry by the International Trade Administration The same report also forecast the country to grow from US billion in to US billion by However despite the markets sheer size several hurdles line the path in moving
The burgeoning costs of healthcare globally are not sustainable The Tufts Center for the Study of Drug Development reports that it costs on average US million and years to develop and obtain regulatory approval for a new drug Driving up drug prices is the fact that only per cent of drug candidates entering clinical trials result in an approved dr...
Statins are a wellestablished class of drugs for the treatment of hypercholesterolemia with a proven longterm safety profile Statins have been shown to reduce the risk of cardiovascular morbidity and mortality in patients with or at risk for coronary heart disease Catapano et al Statin use is expanding and approximately per cent of the world popu...
Imagine being a fly on the wall when I conduct one of my research interviews in a pharmaceutical medtech or diagnostic company Observe what happens when I ask one of my carefully worded questions Please describe your brand strategy Since I research across many countries and disease areas the answers vary in detail But witness enough interviews and...
Preemployment background checks are generally wellaccepted as part of the hiring process in highlyregulated sectors such as the pharmaceutical industry With patents and other valuable intellectual propertyoften worth millionsat risk the potential of sabotage from activist groups theft from industry rivals potential insider threats and not to forget...
Around the world regulators view biosimilars rather differently in terms of designating them as interchangeable with the reference product To date the US has taken a conservative approach not with standing the experience Europe has gained in monitoring thousands of patients who have switched from originator to biosimilar products Meanwhile in Asia...
Pharmacovigilance PV is principally concerned with the identification of Adverse Drug Reactions ADRs and reduction of the associated risks Detection and reporting of ADRs can make prescription of medicinal products much safer and more effective This is possible only if pharmaceutical companies and patients report the ADRs as and when they occur...
Biotherapeutics or biological products are generally produced using living cells or organisms recombinant DNA technology controlled gene expression and antibody technologies It may be manufactured using biotechnology derived from natural sources or produced synthetically Recombinant hormones vaccines monoclonal antibody based products growth factor...
To maximise performance it is time to put the human in the centre of the complex multicultural and dispersed ecosystem of biopharma innovation The Challenge of Sustainable Growth The Current Scenario The pharmaceutical industry has changed dramatically over the past years Despite a range of merger and acquisitions within large companies the...
Driving Forces for Globalisation As the pharmaceutical industry squares off against the challenge of globalisation there is a greater need for content than ever Driven by forces from both the clinical and commercial sides pharmaceutical companies are experiencing rising costs and competitionwhen conducting clinical trials and commercialising existi...
Although its ancestral ideas can be traced back to the late th and early th centuries the concept of PLC as not at a strategic marketing tool is really the child of two later schools of thought Rogers famous Diffusion of Innovation concept with its ideas of innovators early adopter s and laggards showed how and why the adoption of innovative new pr...
Its been a long road beginning with Chinas opendoor policies in the s and membership in the WTO in but Chinas recent and rapid expansion into hightech biopharma manufacturing suggests a future that will involve exports of biologics to Western markets Even before it became the worlds source of toys and electronics China had been animportant exporte...
Asias pharmaceutical manufacturers have seen huge growth in recent years India for example is now the worlds third largest supplier of generic drugs by volume while its domestic market is expected to grow at per cent to per cent CAGR to reach US to US billion in the next decade according to PwC India currently supplies per cent of overthecounte...
India has emerged as one of the worlds fastest growing pharmaceutical markets over the past decade The industry saw a growth of around per cent per annum between and and now stands at US billion The generic drug sector expanded at an even faster pace of per cent per annum during the same period and now accounts for per cent share of global exp...
In the market reached million Francs US million seven per cent growth in value over but market penetration still lags considerably behind the OECD average The reason the generics market is not yet fully developed in Switzerland is in large part due to a lack of incentives for doctors and pharmacists when it comes to prescription The Swiss generi...
Clinical development is a complex puzzle with regulatory requirements epidemiology technology and specific clinical expertise all involved in how efficiently a product is developed and ultimately brought to market Many elements of this puzzle are closely related to geography and vary from one region to another As a result thoughtfully considering t...
While talking about the beginning of Indian pharmaceutical industry it begun in the late s and early s out of the need to meet local shortages and bring down the cost At that time most medicines were imported into India and market was dominated by MNCs Once domestic market was conquered by local companies there was a need to spread their wings in i...
Life science firms exist to meet the needs of patients whilst simultaneously creating value for their shareholders or owners That much is obvious It is also apparent that firms vary greatly in their ability to do these two things the different longevities of companies tell us that What is much less clear is why firms differ so much in their ability...
The Pharma industry at large is faced with challenges due to fast changing global regulations and many countries moving towards adopting a tighter control over drugs The patent cliff has pushed the industry to maximise their revenue from the existing portfolio in the past few years and thus resulted in expanding their market in emerging markets Thi...
Life sciences companies vary enormously in their size structure and processes but almost every firm shares the annual ritual of the strategic plan Whatever the business the intended outcome of this nearuniversal process is an agreed view on how the firm intends to win in the market place As such it ought to be seen as the most important and fundame...
Biopharmaceuticals such as monoclonal antibodies and recombinant proteins have emerged as important lifethreatening therapeutics for the treatment of diseases including cancer Recently products are approved for various human diseases in the United States of America and the European Union Moreover biopharmaceuticals are currently in various stages...
In four global vaccine producersSanofi Pasteur Merck Pfizer and GSKinvested significantly over US m each in global vaccines RD each year This has shrunk from global RD vaccine producers in and in Today there are only two producers for each of the northern hemispheres principle infant adolescent and adult vaccines In the past these RD based pro...
In recent years pharmacovigilance has been recognised as being one of the most important sciences in the health sector and this has led to develop new regulations and guidelines not only in Europe but also in the developing countries around the world The only goal of pharmacovigilance is protecting safety and this of course is also the aim of new r...
Despite the scientific advances and progress in medicine there are only a few effective ways to treat the root causes of many injuries and diseases especially agerelated diseases Regenerative Medicine RM has the ability to repair and regenerate tissues and organs damaged by injuries diseases or the natural progression of age These therapies have th...
